FOI release

FOI request for Keytruda (PBRER body - Section 16. Signal and Risk Evaluation)

This request was refused in part, so we didn't provide some of the information the requester asked for. This may include information where we can neither confirm nor deny that we hold it.

Case reference FOI2026/00638

Received 16 June 2026

Published 10 August 2026

Request

I’m writing this email to submit a Freedom of Information (FOI) request for the latest “Keytruda PBRER – Section 16. Signal and Risk Evaluation”.

Response

See attached

Documents

• FINAL Keytruda (pembrolizumab)-Section-16 Signal and Risk Evaluation_final-redaction.pdf (903.0 KB)
• FOI2026_00638 (redacted).pdf (725.2 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.